Novo Nordisk Lowers Sales Guidance Amid Increased Competition
Novo Nordisk (NVO), the prominent Danish pharmaceutical company known for its innovative weight-loss treatments, has significantly adjusted its sales outlook for the upcoming year. This revision comes as shares of the company experienced an uptick in premarket trading despite the forecast cut.
Sales Growth and New Projections
In light of rising competition from compounded alternatives of its GLP-1 medication, Novo Nordisk has recalibrated its sales expectations for 2025. The company now anticipates a year-over-year sales growth ranging between 13% and 21%, with operating profit growth revised to 16% to 24%, both adjusted for constant currency rates. These figures mark a decline from their earlier projections of 16% to 24% and 19% to 27%, respectively.
CEO Lars Fruergaard Jorgensen stated, “We have reduced our full-year outlook due to lower-than-planned branded GLP-1 penetration,” emphasizing the impact of compounded drug availability in the U.S. market.
Market Response and Analyst Opinions
Analysts at UBS maintained their “buy” rating for Novo Nordisk, suggesting the company’s guidance cut was largely anticipated by the market. They believe a recovery rally is imminent, fueled by three key factors:
- Addressing competition from compounded medications in the U.S.
- Expanding patient access through initiatives like Novo Care and collaborations with CVS.
- Focusing on commercial operations, particularly the rollout of Wegovy outside the U.S.
Q1 Financial Performance
The recent first-quarter results for Novo Nordisk revealed mixed outcomes. The company reported earnings of 6.53 Danish kroner per share, with net sales increasing by 18% year-over-year to reach 78.09 billion kroner. While Ozempic sales reflected a robust growth of 15% to 32.72 billion kroner, Wegovy sales surged by an impressive 83% to 17.36 billion kroner, although this figure fell short of market expectations.
Stock Market Insights
Following these announcements, U.S.-listed shares of Novo Nordisk rose approximately 5.5% in premarket trading, despite previously lagging, with the stock down 23% year-to-date.
The company’s focus remains firm on ensuring the safety and efficacy of its treatments, as well as improving access for patients who rely on their GLP-1 medications.
For more details, visit Investopedia.